Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/vepdegestrant-earns-fda-nod-esr1-mutated-breast-cancer-2026a1000e23?src=rss

Author :

Publish date : 2026-05-01 20:14:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

As RFK Jr. Downplays Rabies, CDC Staff Tells Docs It’s a Daily Threat

FDA OKs Daraxonrasib Pancreatic Cancer Preapproval Access

Related Posts

GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits

First Non-Hormonal Menopause Drug Approved in Scotland

What in the World – How a $2m treatment cured my sickle cell disease

AD Blood Test Helps PCPs Rival Specialists’ Dx Accuracy

Covid inquiry PPE report – a look at the key findings

FDA Approves At-Home Starter Dose of Alzheimer’s Drug

GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits

First Non-Hormonal Menopause Drug Approved in Scotland

What in the World – How a $2m treatment cured my sickle cell disease

AD Blood Test Helps PCPs Rival Specialists’ Dx Accuracy

Covid inquiry PPE report – a look at the key findings

FDA Approves At-Home Starter Dose of Alzheimer’s Drug

Paid Parental Leave for Med School Faculty Often Lacking

Cardiology Crunch: An Aging Nation, Fewer Clinicians

Categories

Archives